Zacks: Brokerages Set $45.00 Target Price for National Research Corp. (NRCIB)
National Research Corp. (NASDAQ:NRCIB) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $45.00 for the company and are anticipating that the company will post $0.19 earnings per share for the current quarter, according to Zacks. Zacks has also assigned National Research Corp. an industry rank of 93 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised National Research Corp. from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Friday, August 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/zacks-brokerages-set-45-00-target-price-for-national-research-corp-nrcib.html
In other National Research Corp. news, CEO Michael D. Hays sold 3,533 shares of the stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $16.19, for a total transaction of $57,199.27. Following the completion of the sale, the chief executive officer now directly owns 6,467,744 shares in the company, valued at approximately $104,712,775.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 39.09% of the company’s stock.
A hedge fund recently bought a new stake in National Research Corp. stock. Willis Investment Counsel purchased a new position in National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned approximately 0.06% of National Research Corp. at the end of the most recent quarter. 2.90% of the stock is currently owned by hedge funds and other institutional investors.
Shares of National Research Corp. (NASDAQ:NRCIB) traded down 1.46% during mid-day trading on Tuesday, hitting $35.67. The stock had a trading volume of 634 shares. The company has a market cap of $863.96 million, a P/E ratio of 43.82 and a beta of 0.28. National Research Corp. has a 1-year low of $31.88 and a 1-year high of $44.60. The firm’s 50 day moving average price is $34.88 and its 200 day moving average price is $35.27.
National Research Corp. (NASDAQ:NRCIB) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $0.18 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.18. National Research Corp. had a return on equity of 33.74% and a net margin of 18.75%. Analysts predict that National Research Corp. will post $0.82 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Friday, September 30th will be given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 5.30%. The ex-dividend date is Wednesday, September 28th. National Research Corp.’s dividend payout ratio is currently 408.52%.
National Research Corp. is a business services company in the Health Care Services industry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.